Session Details

SUN06 Updates in Contact Dermatitis

Sat, Jul 12, 7:30 AM - 8:30 AM
Grand Hall J
1 CME Available Sunrise Session NEW
View Map

DESCRIPTION

The goal of this session is to provide updates on emerging topics in contact dermatitis both to educate colleagues, but also stimulate discussion about novel approaches for contact dermatitis. Topics to be discussed are how to manage contact dermatitis when the allergen cannot be avoided (e.g. diabetic devices), how to counsel patients on allergen avoidance in era in which a wealth of hair and skin care consumer products are available, and the utility of the Day 2 patch test read.

LEARNING OBJECTIVES

1.

Select appropriate treatment/ management strategies for patients unable to avoid contact allergens (e.g. people with devices for diabetes management).

2.

Counsel patients following patch testing regarding identification of allergens and recognition of potential product label inaccuracies.

3.

Evaluate the utility of Day 2 patch test read.

SCHEDULE

12:30 PM

Managing Skin Reactions Associated with Diabetic Devices

Jennifer Chen, MD, FAAD

12:50 PM

Allergen Avoidance After Patch Testing: Counseling Patients in a New Era of Skincare

Jamie Schlarbaum, MD, FAAD

1:10 PM

Timing is Everything: Maximizing Accuracy in Patch Testing

Theodora K Karagounis, MD, FAAD

SPEAKERS

Jennifer Chen, MD, FAAD

Jennifer Chen, MD, FAAD

Theodora K Karagounis, MD, FAAD

Theodora K Karagounis, MD, FAAD

NYU Grossman School of Medicine

Jamie Schlarbaum, MD, FAAD

Jamie Schlarbaum, MD, FAAD

HANDOUTS

Login to view handouts

SPEAKER DISCLOSURES

Jennifer Chen, MD, FAAD

Almirall – Advisory Board(Fees); American Academy of Dermatology – Speaker/Faculty Education(Grants/Research Funding); American Contact Dermatitis Society – Board of Directors(No Compensation Received); Keylika – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Investigator(No Compensation Received);

Theodora K Karagounis, MD, FAAD

No financial relationships exist with ineligible companies.

Jamie Schlarbaum, MD, FAAD

No financial relationships exist with ineligible companies.